Publications
Journal Articles
McMillan, Christopher L. D., Wijesundara, Danushka K., Choo, Jovin J. Y., Amarilla, Alberto A., Modhiran, Naphak, Fernando, Germain J. P., Khromykh, Alexander A., Watterson, Daniel, Young, Paul R. and Muller, David A. (2024). Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein. Journal of General Virology, 105 (1) 001947, 1-6. doi: 10.1099/jgv.0.001947
Wijesundara, Danushka K., Yeow, Arthur, McMillan, Christopher L. D., Choo, Jovin J. Y., Todorovic, Aleksandra, Mekonnen, Zelalem A., Masavuli, Makutiro G., Young, Paul R., Gowans, Eric J., Grubor-Bauk, Branka and Muller, David A. (2023). Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine. Molecular Therapy Nucleic Acids, 34 102056. doi: 10.1016/j.omtn.2023.102056
Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R. and Munro, Trent P. (2023). Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. eBioMedicine, 97 104842. doi: 10.1016/j.ebiom.2023.104842
Albornoz, Eduardo A., Amarilla, Alberto A., Modhiran, Naphak, Parker, Sandra, Li, Xaria X., Wijesundara, Danushka K., Aguado, Julio, Zamora, Adriana Pliego, McMillan, Christopher L. D., Liang, Benjamin, Peng, Nias Y. G., Sng, Julian D. J., Saima, Fatema Tuj, Fung, Jenny N., Lee, John D., Paramitha, Devina, Parry, Rhys, Avumegah, Michael S., Isaacs, Ariel, Lo, Martin W., Miranda-Chacon, Zaray, Bradshaw, Daniella, Salinas-Rebolledo, Constanza, Rajapakse, Niwanthi W., Wolvetang, Ernst J., Munro, Trent P., Rojas-Fernandez, Alejandro, Young, Paul R., Stacey, Katryn J. ... Woodruff, Trent M. (2023). SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Molecular Psychiatry, 28 (7), 2878-2893. doi: 10.1038/s41380-022-01831-0
Williams, Clare M., Roy, Sreeja, Sun, Wei, Furuya, Andrea M., Wijesundara, Danushka K. and Furuya, Yoichi (2022). LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza. Clinical and Translational Immunology, 11 (3) e1381. doi: 10.1002/cti2.1381
Wijesundara, Danushka K., Williams, Clare, Sun, Wei, Furuya, Andrea Marias and Furuya, Yoichi (2021). Fear of influenza resurgence amid covid-19 pandemic: need for effective flu vaccine still exists. Vaccines, 9 (10) 1198, 1198. doi: 10.3390/VACCINES9101198
Chappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21 (10), 1383-1394. doi: 10.1016/S1473-3099(21)00200-0
Watterson, Daniel, Wijesundara, Danushka K., Modhiran, Naphak, Mordant, Francesca L., Li, Zheyi, Avumegah, Michael S., McMillan, Christopher L. D., Lackenby, Julia, Guilfoyle, Kate, van Amerongen, Geert, Stittelaar, Koert, Cheung, Stacey T. M., Bibby, Summa, Daleris, Mallory, Hoger, Kym, Gillard, Marianne, Radunz, Eve, Jones, Martina L., Hughes, Karen, Hughes, Ben, Goh, Justin, Edwards, David, Scoble, Judith, Pearce, Lesley, Kowalczyk, Lukasz, Phan, Tram, La, Mylinh, Lu, Louis, Pham, Tam ... Chappell, Keith J. (2021). Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clinical & Translational Immunology, 10 (4) e1269, e1269. doi: 10.1002/cti2.1269
Isaacs, Ariel, Li, Zheyi, Cheung, Stacey T. M., Wijesundara, Danushka K., McMillan, Christopher L. D., Modhiran, Naphak, Young, Paul R., Ranasinghe, Charani, Watterson, Daniel and Chappell, Keith J. (2021). Adjuvant selection for influenza and RSV prefusion subunit vaccines. Vaccines, 9 (2) 71, 1-14. doi: 10.3390/vaccines9020071
Roy, Sreeja, Williams, Clare M., Wijesundara, Danushka K. and Furuya, Yoichi (2020). Impact of pre-existing immunity to influenza on live-attenuated influenza vaccine (Laiv) immunogenicity. Vaccines, 8 (4) 683, 1-13. doi: 10.3390/vaccines8040683
Wijesundara, Danushka K., Avumegah, Michael S., Lackenby, Julia, Modhiran, Naphak, Isaacs, Ariel, Young, Paul R., Watterson, Daniel and Chappell, Keith J. (2020). Rapid response subunit vaccine design in the absence of structural information. Frontiers in Immunology, 11 592370, 592370. doi: 10.3389/fimmu.2020.592370
Fenix, Kevin, Wijesundara, Danushka K., Cowin, Allison J., Grubor-Bauk, Branka and Kopecki, Zlatko (2020). Immunological memory in imiquimod-induced murine model of psoriasiform dermatitis. International Journal of Molecular Sciences, 21 (19) 7228, 1-13. doi: 10.3390/ijms21197228
Roy, Sreeja, Williams, Clare M., Pardo, Julian, Wijesundara, Danushka K. and Furuya, Yoichi (2020). Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity. Vaccines, 8 (3) 459, 1-6. doi: 10.3390/vaccines8030459
Gummow, Jason, Masavuli, Makutiro G., Mekonnen, Zelalem A., Li, Yanrui, Wijesundara, Danushka K., Shrestha, Ashish C., Voskoboinik, Ilia, Gowans, Eric J. and Grubor-Bauk, Branka (2020). Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus. Vaccines, 8 (1) 53, 1-15. doi: 10.3390/vaccines8010053